Posible exantema pruriginoso secundario a lenalidomida

Vicente Escudero-Vilaplana; Santiago Osorio Prendes; María Sanjurjo Sáez

doi:10.7399/fh.2014.38.6.8176

Posible exantema pruriginoso secundario a lenalidomida

Vicente Escudero-Vilaplana, Santiago Osorio Prendes, María Sanjurjo Sáez

Resumen

Palabras clave

Texto completo:

PDF

Referencias

European Medicines Agency. European Public Assessment Reports: Revlimid. Ficha técnica. [acceso en septiembre 2014]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf.

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refratory multiple myeloma. N Engl J Med. 2007;357(21):2123-32.

Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?. Support Care Cancer. 2004;12:626-33.

Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0, 2010. National Institutes of Health. National Cancer Institute.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.

Nardone B, Wu S, Garden BC, West DP, Reich LM, Lacouture ME. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13(4):424-9.

Boruah PK, Bolesta S, Shetty SM. Possible lenalidomide-induced Stevens-Johnson síndrome during treatment for multiple myeloma. Pharmacotherapy. 2011;31(9):925.

Ribed-Sánchez A, Escudero-Vilaplana V, González-Haba E, Sánchez-Fresneda MN, Herranz-Alonso A, Sanjurjo-Sáez M. Programa integral de atención farmacéutica al paciente en tratamiento con antineoplásicos orales. El Farmacéutico Hospitales. 2013;202:5-13.

DOI: http://dx.doi.org/10.7399%2Ffh.2014.38.6.8176